450 related articles for article (PubMed ID: 16423040)
1. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K
Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040
[TBL] [Abstract][Full Text] [Related]
2. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.
Rowe HM; Lopes L; Ikeda Y; Bailey R; Barde I; Zenke M; Chain BM; Collins MK
Mol Ther; 2006 Feb; 13(2):310-9. PubMed ID: 16275163
[TBL] [Abstract][Full Text] [Related]
3. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
4. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
[TBL] [Abstract][Full Text] [Related]
5. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
[TBL] [Abstract][Full Text] [Related]
6. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
[TBL] [Abstract][Full Text] [Related]
7. Induction of antitumor immunity using bone marrow-generated dendritic cells.
Porgador A; Snyder D; Gilboa E
J Immunol; 1996 Apr; 156(8):2918-26. PubMed ID: 8609412
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 18 transfection enhances antitumor immunity induced by dendritic cell-tumor cell conjugates.
Ju DW; Tao Q; Lou G; Bai M; He L; Yang Y; Cao X
Cancer Res; 2001 May; 61(9):3735-40. PubMed ID: 11325846
[TBL] [Abstract][Full Text] [Related]
9. Differential requirement for CD4 help in the development of an antigen-specific CD8+ T cell response depending on the route of immunization.
Bour H; Horvath C; Lurquin C; Cerottini JC; MacDonald HR
J Immunol; 1998 Jun; 160(11):5522-9. PubMed ID: 9605156
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC.
Maecker HT; Umetsu DT; DeKruyff RH; Levy S
J Immunol; 1998 Dec; 161(12):6532-6. PubMed ID: 9862678
[TBL] [Abstract][Full Text] [Related]
11. Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides.
Nair S; Wearsch PA; Mitchell DA; Wassenberg JJ; Gilboa E; Nicchitta CV
J Immunol; 1999 Jun; 162(11):6426-32. PubMed ID: 10352256
[TBL] [Abstract][Full Text] [Related]
12. Antigen requirements for efficient priming of CD8+ T cells by Leishmania major-infected dendritic cells.
Bertholet S; Debrabant A; Afrin F; Caler E; Mendez S; Tabbara KS; Belkaid Y; Sacks DL
Infect Immun; 2005 Oct; 73(10):6620-8. PubMed ID: 16177338
[TBL] [Abstract][Full Text] [Related]
13. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge.
Krishnan L; Sad S; Patel GB; Sprott GD
Cancer Res; 2003 May; 63(10):2526-34. PubMed ID: 12750276
[TBL] [Abstract][Full Text] [Related]
14. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
[TBL] [Abstract][Full Text] [Related]
15. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
Fernando GJ; Stewart TJ; Tindle RW; Frazer IH
J Immunol; 1998 Sep; 161(5):2421-7. PubMed ID: 9725239
[TBL] [Abstract][Full Text] [Related]
16. Expression mapping using a retroviral vector for CD8+ T cell epitopes: definition of a Mycobacterium tuberculosis peptide presented by H2-Dd.
Aoshi T; Suzuki M; Uchijima M; Nagata T; Koide Y
J Immunol Methods; 2005 Mar; 298(1-2):21-34. PubMed ID: 15847794
[TBL] [Abstract][Full Text] [Related]
17. Functional memory CD8+ T cells can be generated in vivo without evident T help.
Andrews MR; Peters T; Khammanivong V; Leggatt GR; Frazer IH; Fernando GJ
Vaccine; 2004 Dec; 23(6):739-42. PubMed ID: 15542197
[TBL] [Abstract][Full Text] [Related]
18. CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.
Cornet S; Menez-Jamet J; Lemonnier F; Kosmatopoulos K; Miconnet I
Vaccine; 2006 Mar; 24(11):1880-8. PubMed ID: 16300869
[TBL] [Abstract][Full Text] [Related]
19. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
20. Ovalbumin injected with complete Freund's adjuvant stimulates cytolytic responses.
Ke Y; Li Y; Kapp JA
Eur J Immunol; 1995 Feb; 25(2):549-53. PubMed ID: 7875219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
